Advertisement

Topics

Search Results for "Benzodiazepine Multiple Sclerosis"

04:55 EDT 1st October 2016 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

Predicting the severity of multiple sclerosis

Cells in the immune system of patients with multiple sclerosis behave differently from those of healthy individuals. Researchers at Linköping University in Sweden have exploited this difference to de...

Roche’s New Multiple Sclerosis Drug Set for Early FDA Approval

Roche’s Ocrevus (ocrelizumab) has been granted a priority review by the FDA as a treatment for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Researchers lay foundation for innovative treatment of multiple sclerosis

Inhibition of the protein kinase CK2 prevents the development of auto-aggressive T cells, say multiple sclerosis researchers. Multiple sclerosis is the most common chronic inflammatory disease of the ...

Mutation for rare form of multiple sclerosis could be 'genetic smoking gun'

A gene variant has been linked to early onset multiple sclerosis in a small number of cases, lending weight to the hypothesis that genetic factors underlie multiple sclerosis more widely...

Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis

Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented du...

Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis

Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presente...

Children with and without multiple sclerosis have differences in gut bacteria

In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease. Certain types of bacteria were either more or less abun...

Hippocampal inflammation linked to depressive symptoms in patients with multiple sclerosis

Patients with multiple sclerosis have higher rates of depression than the general population, including people with other life-long disabling diseases. Symptoms of multiple sclerosis arise from an abn...

Matching PubMed Articles

Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015.

The main objective of this survey of persons with multiple sclerosis was to describe their employment situation. Secondary objectives were to ascertain when and how multiple sclerosis symptoms first i...

Care Partners and Multiple Sclerosis: Differential Effect on Men and Women.

Caring for someone with multiple sclerosis (MS) can be a stressful experience that requires clinical attention. We investigated the impact of caregiver stress on the emotional well-being and physical ...

Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers.

Antibodies to the RNA-binding protein hnRNP A1 contribute to neurodegeneration in a model of central nervous system autoimmune inflammatory disease.

Neurodegeneration is believed to be the primary cause of permanent, long-term disability in patients with multiple sclerosis. The cause of neurodegeneration in multiple sclerosis appears to be multifa...

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French fo...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement